As of October 26, 2026, UNH closed at $410.70, down 1.77% after reaching an intraday low of $408.35, while the S&P 500 gained 0.70%; at 18.39 places the market in a Neutral regime and the 10-year yield remains essentially flat near 4.99%. The closest sector context is Healthcare Plans and managed care, where UnitedHealthcare and Optum provide a durable, scaled franchise but earnings depend heavily on controlling medical costs. Q3 2026 of $4.69 beat the $4.14 consensus by 13.3%, and FY2026 and FY2027 estimates have risen about 3.9% and 3.8% over 90 days, although actual quarterly declined sequentially from $7.23 to $6.38 to $4.69. At 17.64x forward earnings, a reported of 1.07, and a 7.19% free-cash-flow yield, valuation is reasonable if the recovery persists; the $476.56 mean target implies 16.0% upside, but the $380-$529 target range is wide. The company generated $26.50 billion of free cash flow against $45.78 billion of net debt, while a 3.53% net margin leaves little protection against a renewed claims-cost shock. The long-term chart remains constructive: price is above the , , and , and remains 8.9% above , but the October 26 close below the previously identified $414.12 breakout level invalidates the prior short-term setup. remains positive but its histogram has contracted for two sessions, has eased to 60.1, and has declined over the last two sessions; below-average volume tempers but does not erase the technical warning. The September 28 news coverage cited strong prior healthcare-sector relative performance and UNH's scale, while also flagging regulation and a CorVel claims-integration initiative; that coverage is dated and not evidence of fresh sector inflows. The next earnings report is scheduled for January 12, 2027, 77 days away, so there is no earnings event inside the one-month horizon, although reimbursement and policy developments remain material. The overall and longer-horizon view remains BUY on franchise quality, cash generation, and positive annual estimate revisions, but the one-month view is HOLD until price stabilizes or reclaims $414.12. The key risk is that the margin recovery proves temporary while stagnant revenue provides no offset.
Decision
Live price
$410.70
Recommendation score
66%
66%
Confidence
65%
65%
Outlook by horizon
1M
HOLD
Near
6M
BUY
Mid
1Y
BUY
Long
Primary catalyst
The Q3 2026 earnings release is the most consequential catalyst in the bundle: of $4.69 beat consensus by 13.3%, but the October 13 session ranged from $372.80 to $399.88 and closed at $377.76, showing the market initially reacted with substantial disagreement; the subsequent close below $414.12 now puts the durability of that recovery back in focus.
Treat the overall BUY as a staged 6-12 month accumulation view, not a signal to chase: the close is below the prior $414.12 pivot, so avoid full-size additions until price stabilizes or reclaims that level. New entries are preferable in the $392-$405 support zone after reversal confirmation; keep any existing position at no more than half-normal size while the breakout remains unconfirmed.
Thesis Snapshot
Why It Works
UNH remains a scaled, integrated healthcare franchise with $26.50 billion in free cash flow, a 7.19% FCF yield, a 2.22% dividend yield, and forward earnings estimates that have risen about 3.8%-3.9% over 90 days. Q3 beat consensus by 13.3% after a 29.8% Q2 beat, while the share price remains above its , , and despite the latest pullback. The $476.56 mean target implies 16.0% upside from the current close, and the current forward of 17.64x is not demanding if medical-cost normalization holds. Today's below-average volume does not establish a high-conviction distribution event, although it is not positive accumulation either.
What Breaks It
The uncomfortable counterargument is that this is a margin-recovery trade with no top-line cushion: revenue is down 0.4%, net margin is 3.53%, and actual declined from $7.23 in Q1 2026 to $4.69 in Q3. On October 26 UNH fell while the S&P 500 rose, closed at $410.70 below the prior $412-$421 entry band and below the previously identified $414.12 invalidation level, and moved farther from the prior $461-$500 exit zone; the prior $403 stop has not been hit but is only about 1.9% below the current close. Bears can argue that higher utilization, reimbursement pressure, or regulatory changes reverse the cost-control gains before revenue can offset them. Short interest is 1.98% of float with a 3.11 short ratio; the bundle gives no historical short-interest series, so whether bearish positioning is rising cannot be determined, and the current level is not evidence of a crowded short.
A daily close below $379.50, beneath the October 14 swing low of $382.29, invalidates the technical recovery setup and triggers exit rather than averaging down.
Claims-cost and execution sensitivity: revenue growth is -0.4%, operating margin is 5.82%, net margin is 3.53%, and actual quarterly declined from $7.23 to $6.38 to $4.69 during the first three quarters of 2026.
Technical breakdown risk: the October 26 close of $410.70 is below $414.12 and the day's low was $408.35; a break of $404.04 would expose the at $392.61 and at $390.86, with at $11.49 or 2.80% of price.
Balance-sheet and liquidity risk: net debt is $45.78 billion, about 1.73x free cash flow, while cash-to-debt is 0.38x, the current ratio is 0.74, and the quick ratio is 0.42.
Policy and macro risk: an adverse Medicare Advantage reimbursement or prior-authorization change could pressure a 3.53% net margin; separately, a renewed jump in Treasury yields from around 4.99% or a broad risk-off shock could compress valuation and prompt index-level selling.
Estimate and valuation uncertainty: analyst targets range from $380 to $529, the Q4 estimate has three downward 30-day revisions despite a higher consensus level, and the number of price-target analysts is unavailable.
Watch Next
Next earnings: Jan 12, 2027
The Q3 2026 earnings release is the most consequential catalyst in the bundle: of $4.69 beat consensus by 13.3%, but the October 13 session ranged from $372.80 to $399.88 and closed at $377.76, showing the market initially reacted with substantial disagreement; the subsequent close below $414.12 now puts the durability of that recovery back in focus.
Signal Dashboard
Decision inputs
6 signals
Fundamental
16.0%
Upside to analyst mean target
At $410.70, UNH trades at 26.41x trailing earnings and 17.64x forward earnings, with a reported of 1.065. That is attractive against a common 1.5x growth-stock reference, but the reported 75.9% earnings growth is likely influenced by a depressed comparison base and should not be extrapolated. is 14.68x and price-to-sales is 0.82x; the latter looks optically low, but revenue growth is negative at 0.4%, so it is not sufficient evidence of undervaluation. No peer-multiple or historical-average data are supplied, preventing a verified relative discount assessment. The 7.19% free-cash-flow yield and 2.22% dividend yield support valuation, while the $476.56 mean target implies 16.0% upside and the $490 median implies 19.3%; the case is fairly valued to modestly attractive only if medical-cost normalization continues.
Technical
Neutral
Trend quality
At $410.70, price is about 5.1% above the at $390.86, 4.6% above the at $392.61, and 13.9% above the at $360.43. remains 8.9% above , preserving the established golden-cross structure, but the October 26 close below the prior $414.12 breakout level and the reversal from a $420.86 intraday high put the short-term breakout in question. The longer-term trend remains upward, while the near-term structure has shifted to a support test.
Earnings
77d
Decelerating
Q3 2026 of $4.69 beat the $4.1408 consensus by $0.55, or 13.26%, but actual was down sequentially from $6.38 in Q2 and $7.23 in Q1. On October 13 the shares traded between $372.80 and $399.88 and closed at $377.76 after opening at $397.63, a volatile initial reaction rather than clean confirmation; consensus beats are encouraging but do not by themselves establish the quality of formal management guidance.
News
Mixed-Bullish
Headline tone
The Q3 2026 earnings release is the most consequential catalyst in the bundle: of $4.69 beat consensus by 13.3%, but the October 13 session ranged from $372.80 to $399.88 and closed at $377.76, showing the market initially reacted with substantial disagreement; the subsequent close below $414.12 now puts the durability of that recovery back in focus.
Macro
Neutral
4.99% 10Y / 18.4 VIX
at 18.39 is within the neutral band and the 10-year yield near 4.99% remains a valuation constraint; UNH's defensive cash flows may help in a risk-off rotation, but today's decline while the S&P 500 rose shows that company-specific claims and policy concerns can outweigh the sector's defensive appeal.
Stability
Stable Compounder
Core Anchor
UNH fits the Stable Compounder category because its managed-care and Optum scale, 15.77% , and $26.50 billion of free cash flow support a durable earnings base, but revenue is currently down 0.4% and net margin is only 3.53%. Its 0.615 beta is relatively low, yet a 29.27% 20-day realized volatility and $11.49 show that policy and medical-cost news can still produce abrupt share-price moves. It belongs as a Core Anchor within a diversified healthcare allocation, not as a bond substitute or an oversized single-name holding. Medium drawdown risk and medium thesis durability reflect the strong franchise but uncertain claims-cost recovery, regulatory exposure, and $45.78 billion of net debt.
Analyst Spread
Mean Target
$476.56
High / Low
$380 / $529
Median Target
$490.00
Consensus range
$380 - $529
— analysts
Mean
$380$477$529
Consensus
The $476.56 mean target implies approximately 16.0% upside from $410.70, while the $490 median implies 19.3%; the $529 high implies 28.8% upside and the $380 low implies 7.5% downside. The $149 high-to-low spread indicates substantial disagreement over claims costs, reimbursement, and the durability of the recovery. The price-target analyst count is not supplied; the separate recommendations tally contains 26 opinions, of which 21 are Buy or Strong Buy and five are Hold. Recent target changes include Mizuho at $500 from $493, RBC Capital at $498 from $478, and JPMorgan at $524 from $516, offset by Bernstein at $500 from $512 and TD Cowen maintaining Hold at $402.
Positioning Pulse
Insider Signal
Neutral
Net Bias
No recent activity
Insider Own.
0.2%
Institutional Own.
89.6%
Interpretation
These small, older, unclassified director filings provide no reliable evidence of discretionary insider buying or selling and neither confirm nor undermine management confidence.
Notable activity
The only two rows are director filings shown 149 and 148 days before the snapshot: Valerie C. Montgomery Rice reported 43 shares and Frederick William McNabb III reported 53 shares. Transaction-type and dollar-value fields are blank, so the data do not establish whether these were open-market purchases, sales, grants, or plan-related movements; no recent C-suite cluster or identifiable 10b5-1 pattern is available.
Market Context
Industry
Healthcare Plans
Bearish
Sentiment
-67
Tracked names
1
Grouping
industry
Healthcare Plans industry is currently Bearish with an average recommendation score near 66. capital and conviction are fading across the group, and leadership is still concentrated.
Rotation Drivers
Average recommendation deltas are rolling over across Healthcare Plans industry, which points to capital rotating away from the group.
1 names are rated bullish versus 0 bearish names, keeping the group tone bearish.
Leaders To Watch
Related leaders
No other tracked leaders yet.
Themes
Healthcare Sector Relative Strength
Score: 22
Mixed-Bullish
A September 28 article reported that healthcare had returned 46.9% over its prior six months, outperforming the S&P 500 by 25.5 percentage points, a notable but dated relative-strength signal. UNH is up 9.06% over the latest one-month period, but on October 26 it fell 1.77% while the S&P 500 gained 0.70%. The available bundle contains no current sector ETF flows or updated peer returns, so fresh capital rotation into healthcare is not confirmed.
at 18.39 and a 4.99% 10-year yield keep defensive healthcare relevant, but UNH's October 26 underperformance makes current leadership uncertain.
The September 28 article cited healthcare's 46.9% six-month return and 25.5-percentage-point outperformance versus the S&P 500 on its then-current lookback.
UNH's 9.06% one-month return remains positive, but its October 26 decline against a rising S&P 500 is a caution against treating sector-wide leadership as freshly confirmed.
Managed-Care Margin Recovery
Score: 38
Mixed-Bullish
UNH's Q2 and Q3 2026 surprises of 29.8% and 13.3%, together with higher FY2026 and FY2027 consensus estimates, support a recovery in managed-care profitability. The theme is earnings- and cost-control-led rather than revenue-led: revenue growth is -0.4%, and quarterly declined from $7.23 in Q1 to $4.69 in Q3. The thesis is therefore improving but remains vulnerable to renewed utilization or reimbursement pressure.
The latest Q3 beat and roughly 3.8%-3.9% 90-day increases in annual estimates reinforce the recovery narrative, while the October 26 price decline below $414.12 shows that confirmation is incomplete.
Q2 and Q3 2026 beat consensus by 29.8% and 13.3%, respectively, and FY2026/FY2027 estimates are up about 3.9%/3.8% over 90 days.
The recommendations tally has 21 Buy or Strong Buy opinions out of 26, but the latest quarter has three downward 30-day estimate revisions, and sequential reported is lower.
Key Stats
23 metrics total
Market Cap
$368.64B
P/E (TTM)
26.4
Forward P/E
17.6
Revenue Growth
-0.4%
ROE
15.8%
Beta
0.62
Full Metric Set
17 additional stats
Valuation Stack
Multiples and cash-flow framing.
Price / Sales
0.8
Price / Book
3.6
EV / EBITDA
14.7
Quality & Balance Sheet
Margins, leverage, and liquidity.
Gross Margin
20.0%
Operating Margin
5.8%
Debt / Equity
70.4
Current Ratio
0.74x
Quick Ratio
0.42x
Positioning & Range
Short interest and 52-week location.
Short % Float
2.0%
Short Ratio
3.11x
52W High
$461.62
52W Low
$255.97
From 52W High
-11.0%
From 52W Low
60.5%
Company Classification
Sector and industry context.
Sector
Healthcare
Industry
Healthcare Plans
Additional Signals
Free Cash Flow
$26501249024.00
Detailed Analysis
Valuation
At $410.70, UNH trades at 26.41x trailing earnings and 17.64x forward earnings, with a reported of 1.065. That is attractive against a common 1.5x growth-stock reference, but the reported 75.9% earnings growth is likely influenced by a depressed comparison base and should not be extrapolated. is 14.68x and price-to-sales is 0.82x; the latter looks optically low, but revenue growth is negative at 0.4%, so it is not sufficient evidence of undervaluation. No peer-multiple or historical-average data are supplied, preventing a verified relative discount assessment. The 7.19% free-cash-flow yield and 2.22% dividend yield support valuation, while the $476.56 mean target implies 16.0% upside and the $490 median implies 19.3%; the case is fairly valued to modestly attractive only if medical-cost normalization continues.
Balance Sheet
Debt-to-equity of 70.43% (about 0.70x) is moderate, but cash of $28.55 billion against $74.33 billion of debt leaves $45.78 billion of net debt, equivalent to about 1.73x annual free cash flow and 12.4% of market capitalization. Free cash flow is $26.50 billion and operating cash flow is $26.19 billion; because reported free cash flow slightly exceeds operating cash flow and no capex reconciliation is provided, the cash-flow definitions merit caution. of 15.77% and of 5.24% are solid but not exceptional. Current and quick ratios of 0.74 and 0.42 are low by generic corporate standards; claims-liability composition is not provided, so liquidity should not be assumed to have a large cushion.
Growth
Revenue growth is negative at 0.4% year over year, while reported earnings growth is 75.9%, a sharp divergence that makes cost control rather than volume growth the current earnings driver. Q3 2026 of $4.69 was 60.6% above Q3 2025, but actual quarterly declined from $7.23 in Q1 2026 to $6.38 in Q2 and $4.69 in Q3; seasonality may contribute, but the sequential trend is decelerating. FY2026 consensus is $20.591, up about 3.9% from 90 days earlier, and FY2027 is $23.286, up about 3.8%. Current margin data are available, but a time series is not supplied, so the direction of margin expansion or contraction cannot be confirmed.
Business Quality
UnitedHealth combines a large health-insurance business with Optum services, and the September 28 article in the bundle describes more than 100 million people served and a workforce above 400,000. Gross margin is 20.05%, operating margin 5.82%, margin 6.42%, and net margin 3.53%; is 15.77% and is 5.24%. Scale, integrated services, and substantial free cash flow support a durable franchise and a reasonable market-level multiple, but thin net margins leave earnings highly sensitive to utilization, reimbursement, and execution. Institutional ownership is 89.59% and insider ownership is 0.25%, indicating highly institutional ownership without a meaningful insider-ownership signal.
Capital Allocation
Cash of $28.55 billion and debt of $74.33 billion leave $45.78 billion of net debt, so balance-sheet capacity is adequate but not unlevered. The 2.22% dividend yield and 57.56% payout ratio appear supported by reported free cash flow of $26.50 billion, subject to the cash-flow reconciliation caveat. The bundle lists 897.6 million shares outstanding but provides no share-count history, repurchase authorization, or reliable buyback record; accretion or dilution cannot be assessed. Capital allocation is therefore supported by internal cash generation and the dividend, but evidence that repurchases or other deployment are creating incremental shareholder value is unavailable.
Estimate Revisions
Annual estimate momentum is positive: FY2026 of $20.591 is about 3.9% above its 90-day level, with two upward and zero downward 30-day revisions; FY2027 of $23.286 is about 3.8% above its 90-day level, although its 30-day revision count includes one downward revision. The near-term quarter is more mixed: the current estimate of $2.263 is up about 7.6% from 30 days ago, yet the revision count shows three downward changes over 30 days and one over seven days. The following quarter estimate of $8.168 is only about 0.6% above its 30-day level. The recommendations tally is 6 Strong Buy, 15 Buy, and 5 Hold, versus 7, 15, and 4 one month earlier; there were no formal rating upgrades or downgrades in the 90-day data. Target-price actions are mixed, with Mizuho, RBC Capital, and JPMorgan raising targets and Bernstein lowering its target.